| 001 | 289462 | ||
| 005 | 20250819132624.0 | ||
| 024 | 7 | _ | |a 10.1016/j.pulmoe.2024.03.003 |2 doi |
| 024 | 7 | _ | |a pmid:38614857 |2 pmid |
| 024 | 7 | _ | |a 2531-0429 |2 ISSN |
| 024 | 7 | _ | |a 2531-0437 |2 ISSN |
| 024 | 7 | _ | |a altmetric:164748037 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00784 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Safi, S. |b 0 |
| 245 | _ | _ | |a Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study. |
| 260 | _ | _ | |a Amsterdam |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726657602_8429 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Adjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 %) patients in the discovery cohort and 50 of 93 (54 %) in the validation cohort received adjuvant chemotherapy; forty-four (85 %) patients in the discovery cohort and 37 (74 %) in the validation cohort received four cycles as planned. In patients with low IL-1β-expressing tumors, RFS and OS were worse after adjuvant chemotherapy than after observation. The limited effect of adjuvant chemotherapy for patients with low IL-1β-expressing tumors was confirmed in the validation cohort. Additionally, RFS and OS were prolonged by adjuvant chemotherapy only in patients with high IL-1β-expressing tumors in the validation cohort.This study identified and validated low tumor IL-1β expression as a potential biomarker of a limited response to adjuvant platinum-based chemotherapy after complete resection of pulmonary adenocarcinoma. This finding has the potential to inform adjuvant treatment decisions. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Biomarkers |2 Other |
| 650 | _ | 7 | |a Cytokines |2 Other |
| 650 | _ | 7 | |a IL-1β |2 Other |
| 650 | _ | 7 | |a Lung neoplasms |2 Other |
| 650 | _ | 7 | |a Tumor microenvironment |2 Other |
| 700 | 1 | _ | |a Krzykalla, J. |0 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |b 1 |u dkfz |
| 700 | 1 | _ | |a Hoffmann, H. |b 2 |
| 700 | 1 | _ | |a Benner, A. |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 3 |u dkfz |
| 700 | 1 | _ | |a Bischoff, H. |b 4 |
| 700 | 1 | _ | |a Eichhorn, M. |b 5 |
| 700 | 1 | _ | |a Kriegsmann, M. |b 6 |
| 700 | 1 | _ | |a Poschke, I. |b 7 |
| 700 | 1 | _ | |a Stögbauer, F. |b 8 |
| 700 | 1 | _ | |a Umansky, Ludmila |0 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45 |b 9 |
| 700 | 1 | _ | |a Mogler, C. |b 10 |
| 700 | 1 | _ | |a Weichert, W. |b 11 |
| 700 | 1 | _ | |a Winter, H. |b 12 |
| 700 | 1 | _ | |a Beckhove, P. |b 13 |
| 700 | 1 | _ | |a Muley, T. |b 14 |
| 773 | _ | _ | |a 10.1016/j.pulmoe.2024.03.003 |g p. S2531043724000436 |0 PERI:(DE-600)3009651-0 |p nn |t Pulmonology |v nn |y 2024 |x 2531-0429 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289462/files/Low%20tumor%20interleukin-1%20expression%20predicts%20a%20limited%20effect%20of%20adjuvant%20platinum-based%20chemotherapy%20for%20patients%20with%20completely%20resected%20lung%20adeno.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289462/files/Low%20tumor%20interleukin-1%20expression%20predicts%20a%20limited%20effect%20of%20adjuvant%20platinum-based%20chemotherapy%20for%20patients%20with%20completely%20resected%20lung%20adeno.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:289462 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PULMONOLOGY : 2022 |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-09-15T16:03:54Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-09-15T16:03:54Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Double anonymous peer review |d 2022-09-15T16:03:54Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-27 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b PULMONOLOGY : 2022 |d 2023-10-27 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A370-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::